

Bölüm 47

GnRH ANALOGLARI: FİZYOLOJİ VE YÜT'DE KULLANIMI

Doç. Dr. Abdullah KARAER
Prof. Dr. Önder ÇELİK

ÜNİTE 4

YÜT'de çok sık kullanılan birçok protokolün bir parçası olan agonist ve antagonistlerin etki mekanizmaları, elde edilmiş şekilleri, klinik kullanımdaki ve protokollerdeki önemini kavramak için GnRH'ü yakından tanımakta fayda vardır. Klinisyenler klinik gebelik oranlarını artırmak için infertil endometriozis olgularında ART öncesi 3-6 ay süreyle GnRH agonistleri reçete edebilir. Endometriozisle ilişkili ağrıyı azaltmak için de analog verilebilir. Ancak hormonal tedavilerin ağrıyı azaltmak açısından birinin diğerine üstünlüğü yoktur. GnRH antagonistlerinin endometriozisle ilişkili ağrının tedavisinde etkili olduğuna dair kanıt yoktur. **Editorial**

Giriş

Fizyolojik Prensipler

- GnRH
- GnRH reseptör
- GnRH-r sinyal iletimi
- GnRH salınımı
- GnRH'nin hipofizer ve ekstrapofizer etkisi

GnRH Agonistleri

- GnRH agonistlerinin etki mekanizması
- GnRH agonistlerinin ekstrapofizer etkisi

GnRH Agonistlerinin Klinik Kullanımı

- Uygulama şekilleri (Depo ya da günlük)
- Doz
- GnRH analoglarının İVF amaçlı klinik kullanımı
- GnRH agonistlerine ilave ilaçların İVF'de kullanımı
- GnRH agonistlerinin LH piki indüklemeye amaçlı kullanımı
- Dezavantajlar / Yan etkiler

Giriş

Bu bölümde ilk olarak GnRH sistemi ve çalışma prensipleri, analog ve antagonistlerin ortaya çıkış süreçleri ve etki mekanizmaları ele alınacak takiben YÜT'de kullanım amaçları ve kullanım şekilleri ayrıntılı olarak gözden geçirilecektir. Takibeden bölümde ise agonistlerin endometriozis olgularında kullanımı kapsamlı bir şekilde okuyucu ile paylaşılacaktır. Bu iki bölümün amacı YÜT ile ilgilenen okurlara GnRH'a dair temel ve klinik bilgilerin özet, pratik ve anlaşılır tarzda aktarılmasını sağlamaktır.

1978 yılındaki ilk defa canlı doğum ile sonuçlanan prosedür de dâhil ilk dönemlerde invitro fertilizasyon (İVF), doğal -stimule edilmeyen- sikluslarda deneniyordu (1). 1980'lerin ilk yıllarında doğal siklusun preovulatuvar fazında tek bir oosit elde etmek terk edilip çok sayıda oosit elde edilme-

Kaynaklar

- Streptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. *Lancet* 1978;2 (8085):366.
- Loumaye E. The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonist during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. *Hum Reprod* 1990;5: 357-376
- Lejune B, Degueldre M, Camus M, Vekemans M, Opsomer L, Leroy F. In vitro fertilization and embryo transfer as related to endogenous luteinizing hormone rise or human chorionic gonadotropin administration. *Fertil Steril* 1986; 45: 377- 383
- Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation in-vitro fertilization using buserelin and gonadotropins. *Lancet* 1984; 2: 1284-1285
- Karten MJ & Rivier JE. Gonadotropin-releasing hormone analog design. Structure- function studies toward the development of agonist and antagonist: rationale and perspective. *Endocr Rev* 1986; 7 :44-66
- Schally AV, Arimura A, Baba Y, Nair RM, Matsuo H, Redding TW, Debujulk L. Isolation and properties of the FSH and LH- releasing hormone. *Biochem Biophys Res Commun* 1971; 43: 393-399
- Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. *J Endocrinol* 2005; 184: 11–28.
- Millar RP. GnRHs and GnRH receptors. *Anim Reprod Sci* 2005;88:5–28.
- Pawson AJ, McNeilly AS. The pituitary effects of GnRH. *Anim Reprod Sci* 2005;88:75–94
- Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. *Endocr Rev* 1997;18:180–205.
- Maiti K, Li JH, Wang AF, Acharjee S, Kim WP, Im WB, Kwon HB, Seong JY. GnRH-II analogs for selective activation and inhibition of nonmammalian and type-II mammalian GnRH receptors. *Mol Cells* 2003;16:173–179.
- Millar RP. GnRH II and type II GnRH receptors. *Trends Endocrinol Metab* 2003;14:35–43
- Yang-Feng TL, Seeburg PH, Francke U. Human LHRH gene is located short arm of chromosome 8 (region 8p11.2-p21). *Somat Cell Molec Genet* 1986; 12:95-100
- Sherwood NM, Lovejoy DA, Coe IR. Origin of mammalian gonadotropin-releasing hormones. *Endocr Rev* 1993;14: 241–254.
- Carolsfeld J, Powell JF, Park M, Fischer WH, Craig AG, Chang JP, Reivizer JE, Sherwood NM. Primary structure and function of three gonadotropin-releasing hormones, including a novel form, from an ancient teleost, herring. *Endocrinology* 2000; 141: 505-512
- Pawson AJ, McNeilly AS. The pituitary effects of GnRH. *Anim Reprod Sci* 2005;75-94
- Millar RP, Lu Z-L, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. *Endocr Rev* 2004;25:235–275
- Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in human. *Endocr Rev* 2005; 26: 283-306
- Casan EM, Raga F, Polan ML. GnRH mRNA and protein expression in human preimplantation embryos. *Mol Hum Reprod* 1999; 5:234-239
- Metallinou C, Asimakopoulos B, Schröder A and Nikolettos N. Gonadotropin-Releasing Hormone in the Ovary. *Reprod Sci* 2007;14: 737- 749
- White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. *Proc Natl Acad Sci USA* 1998; 95: 305-309
- Rissman EF, Alones V, Craig-Veit CB, Millam JR. Distribution of chicken II gonadotropin-releasing hormone in mammalian brain. *J Comp Neurol* 1995;357:524–531.
- Ramakrishna N, Rajamahendran R, Lin YM, Leung PC. GnRH in non hypothalamic reproductive tissues. *Anim Reprod Sci* 2005; 88:95–113.
- Gründker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. *Reprod Biol Endocrinol* 2003; 1: 65
- Kang SK, Choi KC, Cheng KW, Nathwani PS, Auer-sperg N, Leung PC. Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. *Endocrinology* 2000; 141: 72-80
- Chegin N, Rong H, Dou Q, Kipersztok S, Williams RS. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. *J Clin Endocrinol Metab* 1996; 81:3215-3221
- Cheng KW, Nathwani Ps, Leung PC. Regulation of human gonadotropin-releasing hormone receptor gene expression in placental cells. *Endocrinology* 2000; 141: 2340-2349
- Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC. Sequence alignment of the G-protein coupled receptor superfamily. *DNA Cell Biol* 1992; 11: 1-20
- Blomenrohr M, Heding A, Sellar R, Leurs R, Rogerd J, Eidne KA, Willars GB. Pivotal role for the cytoplasmic carboxy-terminal tail of a nonmammalian gonadotropin-releasing hormone receptor in cell surface expression, ligand binding, and receptor phosphorylation and internalization. *Mol Pharmacol* 1999; 56: 1229- 1237
- Vrecl M, Heding A, Hanyaloğlu A, Taylor PL, Eidne KA. Internalization kinetics of the gonadotropin-releasing hormone (GnRH) receptor. *Pflugers Arch* 2000; 439: 19-20
- Huime JA, Homburg R, Lambalk CB. Are GnRH antagonist comparable to agonist for use in IVF. *Human Reprod* 2007; 22:2805-2813
- Leung PC, Squire J, Peng C, Fan N, Hayden MR, Olofsson J. Mapping of the gonadotropin-releasing hormone (GnRH) receptor gene to human chromosome 4q21:2 by fluorescence in situ hybridization. *Mamm Genome* 1995; 6: 309-310
- Cheng KW, Chow BK, Leung PC. Functional mapping of a placenta-specific upstream promoter for human gonadotropin-releasing hormone receptor gene. *Endocrinology* 2001;142: 1506-1516

34. Cheng CK, Yeung CM, Chow BK, Leung PC. Characterization of a new upstream gonadotropin-releasing hormone receptor promoter in human ovarian granulosa-luteal cells. *Mol Endocrinol* 2002; 16: 1552-1564
35. Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M., Lincoln G, Sellar R, Faurholm B, Scobie G, Kuesner R, Terasawa E, Katz A. A novel mammalian receptor for the evolutionarily conserved type II GnRH. *Proc Natl Acad Sci USA* 2001; 98: 9636-9641
36. Neil JD, Duck LW, Sellers JC, Musgrove LC. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. *Biochem Biophys Res Commun* 2001; 282: 1012-1018
37. Eicke N, Gunthert AR, Viereck V, Siebold D, Be'he' M, Becker T, Emons G, Gründker C. GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. *Eur J Endocr* 2005; 153: 605-612
38. Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR, Millar RP. A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q. *Endocrinology* 2003; 144: 423-436.
39. Burger LL, Haisenleder DJ, Dalkin AC, Marshall JC. Regulation of gonadotropin subunit gene transcription. *J Mol Endocrinol* 2004; 33: 559-584.
40. Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. *Eur J Obstet Gynecol* 2004; 115S: 44-56
41. Conn PM, Rogers DC, Seay SG. Structure-function relationship of calcium ion channel antagonists at pituitary gonadotrope. *Endocrinology* 1983; 113: 1592-1595
42. Conn PM, Chafoules J, Rogers D, Means AR. Gonadotropin releasing hormone stimulates calmodulin distribution in rat pituitary. *Nature* 1981; 292: 264-265
43. McArdle CA, Conn PM. Hormone-stimulated redistribution of gonadotrope protein kinase C in vivo: dependence on Ca^{+2} influx. *Mol Pharmacol* 1986; 29: 570-576
44. Conn PM, Rogers DC, Sheffield T. Inhibition of gonadotropin-releasing hormone-stimulated luteinizing hormone release by pimozide: evidence for a site of action after calcium mobilization. *Endocrinology* 1981; 109: 1122-1126
45. Andrews WV, Conn PM. Gonadotropin-releasing hormone stimulates mass changes in phosphoinositides and diacylglycerol accumulation in purified gonadotrope cell cultures. *Endocrinol* 1986; 118: 1148-1158
46. McArdle CA, Huckle WR, Conn PM. Phorbol esters reduce gonadotrope responsiveness to protein kinase C activators but not to Ca^{+2} -mobilizing secretagogues: does protein kinase C mediate gonadotropin-releasing hormone action? *J Biol Chem* 1987; 262: 5028-5035
47. Waldhauser F, Weibenbacher G, Frish H, Pollak A. Pulsatile secretion of gonadotropins in early infancy. *Eur J Pediatr* 1981; 137: 71-74
48. Jakacki RI, Kelch RP, Sauder Se, Lloyd JS, Hopwood NJ, Marshall JC. Pulsatile secretion of luteinizing hormone in children. *J Clin Endocrinol Metab* 1982; 55: 453-458
49. Boyar RM, Rosenfeld RS, Kapen S, Finkelstein JW, Roffwarg HP, Weitsman ED, Hellman L. Human puberty. Simultaneous augmented secretion of luteinizing hormone and testosterone during sleep. *J Clin Invest* 1974; 54: 609-618
50. Kapen S, Boyar RM, Finkelstein JW, Hellman L, Weitsman ED. Effect of sleep-wake cycle reversal on luteinizing hormone secretory pattern in puberty. *J Clin Endocrinol Metab* 1974; 39: 293-299
51. Filicori M, Santoro N, Merriam GR, Growley WF Jr. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. *J Clin Endocrinol Metab* 1986; 62: 1136-1144
52. Winters SJ, Troen P. A reexamination of pulsatile luteinizing hormone secretion in primary testicular failure. *J Clin Endocrinol Metab* 1983; 57: 432-435
53. Yen SS, Tsai CC, Naftolin F, Vandenberg G, Ajabor L. Pulsatile patterns of gonadotropin release in subjects with and without ovarian function. *J Clin Endocrinol Metab* 1972; 34: 671-675
54. Neill JD, Musgrove LC, Duck LW. Newly recognized GnRH receptors: function and relative role. *Trends Endocrinol Metab* 2004; 15: 383-392
55. Kim HH, Mui KL, Nikrodhanond AA, Tamayo NC. Regulation of gonadotropin-releasing hormone in non-hypothalamic tissues. *Semin Reprod Med* 2007; 25: 326-336
56. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. *N Eng J Med* 1990; 324: 93-103
57. Ortmann O, Weiss JM, Diedrich K. Gonadotropin-releasing hormone (GnRH) and GnRH agonist: mechanism of action. *Reprod Biomed Online* 2002; 5(Suppl 1): 1-7
58. Casper RF, Erickson GF, Rebar RW, Yen SS. The effect of luteinizing hormone-releasing factor and its agonist on cultured human granulosa cells. *Fertil Steril* 1982; 37: 406-409
59. Lanzole A, Panetta V, Di Simone N, Arno E, Fulghesu AM, Caruso A, Mancuso S. Effect of gonadotropin-releasing hormone and related analogue on human luteal cell function in vitro. *Hum Reprod* 1989; 4: 906-909
60. Weiss JM, Oltmanns K, Gürke EM, Polack S, Eick F, Felberbaum R, Diedrich K, Ortmann O. Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. *Eur J Endocrinol* 2001; 144: 677-685
61. Asimakopoulos B, Nikolettos N, Nehls B, Diedrich K, Al-Hasani S, Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. *Fertil Steril* 2006; 86: 636-641
62. Parinaud J, Beau A, Bourreau E, Vieitez G, Pontonnier G. Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells. *Fertil Steril* 1988; 50: 597-602

63. Pelicer A, Miro F. Steroidogenesis in vitro of human granulosa luteal cells pretreated in vivo with gonadotropin-releasing hormone analogues. *Fertil Steril* 1990; 54: 590-596
64. Miro F, Sampaio MC, Tarin JJ, Pellicer A. Steroidogenesis in vitro of human granulosa-luteal cells pre-treated in vitro with two gonadotropin releasing hormone analogues employing different protocols. *Gynecol Endocrinol* 1992; 6: 77-84
65. Bussenot I, Azoulay- Barjonet C, Parinaud J. Modulation of the Steroidogenesis of cultured human granulosa- lutein cells by gonadotropin-releasing hormone analogs. *J Clin Endocrinol metab* 1993; 76:1376- 1379
66. Guerrero HE, Stein P, Asch RH, deFried EP, Tesone M. Effect of a gonadotropin- releasing hormone agonist on luteinizing hormone receptors a steroidogenesis in ovarian cells. *Fertil Steril* 1993; 59:803-808
67. Gaetje R. Influence of gonadotropin releasing hormone (GnRH) and a GnRH-agonist on granulosa cell steroidogenesis. *Clin Exp Obstet Gynecol* 1994; 21:164-169
68. Uemura T, Namiki T, Kimura A, Yanagisawa T, Minaguchi H. Direct effects of gonadotropin-releasing hormone on the ovary rats and humans. *Horm Res* 1994;41:7-13
69. Dor J, Bieder D, Shulman A, Levron JR, Shine S, Mashiac S, Rabinovici J Effects of gonadotrophin releasing hormone agonists on human ovarian steroid secretion in vivo and in-vitro results of a prospective randomized in-vitro fertilization study. *Hum Reprod* 2000;15: 1225-1230
70. Ortmann O, Weiss JM, Dietrich K. Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists. *Hum Reprod* 2001; 16: 608-611
71. Saadat P, Boostanfar R, Slater CC, Taugeman DE, Stanczyk FZ, Paulson RJ. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists. *Fertil Steril* 2004; 82:167-171
72. Kawamura K, Fukuda J, Kumagai J, Shimizu Y, Kodama H, Nakamura A, Tanaka T. Gonadotropin-releasing hormone I analog acts as an antiapoptotic factor in mouse blastocysts. *Endocrinology* 2005; 146:4105-4116.
73. Torres Mde M, Donadio N, Donadio NF, Brandao AC, Heck B. Comparison of embryo implantation in Wistar rats that underwent ovarian stimulation using exogenous gonadotropins associated with cetrorelix acetate or leuprolide acetate. *Fertil Steril* 2005;84:1235-1240.
74. Klemmt PA, Liu F, Carver JG, Jones C, Brosi D, Adamson J, Mardon HJ, Mc Veigh E. Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. *Hum Reprod* 2009;24:2187-2192
75. van Loenen AC, Huirne JA, Schats R, Hompes PG, Lambalk CB. GnRH agonists, antagonists, and assisted conception. *Semin Reprod Med* 2002; 20:349-364
76. Dondeti P, Zia H, Needham TE. Bioadhesive and formulation parameters affecting nasal absorption. *Int. J. Pharm* 1996; 127: 115-133.
77. Jadhav KR, Gambhire MN, Shaikh IM, Kadam VJ, Pisal SS. Nasal drug delivery system-factors affecting and applications. *Curr. Drug Teraphy* 2007; 2: 27-38.
78. Anik ST, McRae G, Nerenberg C, Worden A, Foreman J, Hwang JY, Kushinnsky S, Jones RE, Vickery B Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)6]LHRH, in rhesus monkeys. *J. Pharm. Sci.* (1984) 73 684-685
79. Chaplin MD. Bioavailability of nafarelin in healthy volunteers. *Am. J. Obstet Gynecol* 1992; 166: 762-765.
80. Franco JG Jr, Baruffi RL., Mauri AL, Petersen CG, Chufallo JE, Felipe V Garbellini E . Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program. *J. Assist. Reprod. Genet.* 2001;18 (11) 593-597.
81. Broekmans FJ., Bernardus RE, Berkhout G, Schoemaker J. Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. *Gynecol. Endocrinol.* 1992; 6: 153-161.
82. Herman A, Ron El R, Golan A, Nachum H, Soffer Y, Caspi E. Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long -acting agonist of gonadotropin-releasing hormone. *Hum Reprod* 1992;7:465-468
83. Albuquerque LE, Saconato H, Maciel MC. Depot versus daily administration of gonadotropin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. *Cochrane Database Syst Rev* 2002; 3: CD002808 .
84. Ben-Rafael Z, Lipitz S, Bider D Mashiach H. Ovarian hyporesponsiveness in combined gonadotropin- releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. *Fertil Steril* 1991; 55:272-275
85. Broekmans FJ, Hompes PG, Lambalk CB, Schoute B, Broeders A, Schoemaker J. Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin. *Hum Reprod* 1996; 11: 55-60
86. Janssens RM, Vermeiden JP, Lambalk CB, Schats R, Shomaker J. Gonadotrophin- releasing hormone agonist dose- dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF. *Hum Reprod* 1998; 13: 2386-2391
87. Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekels- Mombrag LT, Schumacker J. Dose- finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. *Hum Reprod* 2000;15: 2333- 2340
88. Elgendy M, Afnan M, Holder R, Lashen H, Afifi Y, Lenton W, Sharif K. Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in- vitro fertilization outcome. *Hum Reprod* 1998;13: 2382- 2385
89. Feldberg D, Fahri J, Ashkenazi J, dicker D, Shalev J, Ben-Rafael Z. Minidose gonadotropin-releasing

- hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. *Fertil Steril* 1994; 62: 343-346
90. Huirne JA, Lambalk CB, van Loenen AC, Schats R, Hompes PG, Fauser BC, Mavcklon NS. Contemporary pharmacological manipulation in assisted reproduction. *Drugs* 2004; 64: 297-322
 91. Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. *Cochrane Database Syst Rev* 2000; 1: CD001299.
 92. Maheshwari A, Bhattacharya S, Daya S, Gibreel AF, Siristatidis CS. Gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproductive treatment (Protocol). *Cochrane Database Syst Rev* 2009; 3: CD006919.
 93. Berek JS. *Novak's Gynecology*. 13. Edition. p.1025
 94. Kahraman S, Karlıkaya G. Ovulasyon İndüksiyonu. 2009. s.69
 95. Sbracia M, Farina A, Poverini R, Morgia F, Schimberni M, Aragona C. Short versus long gonadotropin-releasing hormone analogue suppression protocols for superovulation in patients > or = 40 years old undergoing intracytoplasmic sperm injection, *Fertil. Steril.* 2005;84: 644–648.
 96. Chang SY, Lee CL, Wang ML, Hu ML, Lai YM, Chang MY, Soong YK. No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist, *Fertil. Steril* 1993;59: 183–186.
 97. Dimitry ES, Oskarsson T, Conaghan J, Margara R, Winston RM. Beneficial effects of a 24 h delay in human chorionic gonadotrophin administration during in vitro fertilization treatment cycles. *Hum. Reprod* 1991; 6: 944–946.
 98. Pellicer A, Simon C, Miro F, Castellvi RM, Ruiz A, Ruiz M, Perez M, Bonilla-Musoles F. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle. *Hum Reprod* 1989;4:285-289
 99. Kondavetti- Gordon U, Harrison RF, Barry- Kinsella C, Gordon AC, Drudy L, Cottell E. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone for invitro fertilization program. *Fertil Steril* 1996; 66:582-586
 100. San Roman GA, Surrey ES, Judd HL, Kerin JF. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist. *Fertil Steril* 1992; 58: 744-749
 101. Homburg R, Arman NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinizing hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. *BMJ* 1988; 297:1024–1026.
 102. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. *Human Reproduction* 2000; 15: 1003–1008.
 103. Simons AH, Roelofs HJ, Schmoutziguer AP, Roozenburg BJ, vant Hof-van den Brink EP, Schoonderwoerd SA. Early cessation of triptorelin in in vitro fertilization: a double blinded, randomized study. *Fertility and Sterility* 2005;83:889–896.
 104. Dal Prato L, Borini A, Coticchio G, Cattoli M, Flamigni C. Halfdose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study. *Human Reproduction* 2004;19:2200–2205.
 105. Fujii S, Sagara M, Kudo H, Kagiya A, Sato S, Saito Y. A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization. *Fertility and Sterility* 1997;67:1166–1168.
 106. Dirnfeld M, Fruchter O, Yshai D, Lissak A, Ahdut A, Abramovici H. Cessation of gonadotrophin-releasing hormone analogue (GnRH_a) upon down-regulation versus conventional long GnRH-a protocol in poor responders undergoing in vitro fertilization. *Fertility and Sterility* 1999;72:406–411.
 107. Cedrin-Durnerin I, Bidart JM, Robert P, Wolf JP, Uzan M, Hugues JM. Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for *in-vitro* fertilization. *Hum Reprod* 2000; 15: 1009- 1014
 108. Garcia-Velasco JA, Isaza V, Requena A, Martinez-Salazar FJ, Landazabal A, Remohi J, Pellicer A, Simon C. High doses of gonadotrophins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: a prospective, randomized, controlled trial. *Hum Reprod* 2000; 15: 2292-6
 109. Muasher SJ. Treatment of low responders. *J Assist Reprod Genet* 1993; 10: 112-1 14
 110. Smitz J, Bollen N, Camus M, Devroey P, Wisanto A, Van Steirteghem AC. Short-term use of buserelin in combination with human menopausal gonadotrophins for ovarian stimulation for in-vitro fertilization in endocrinologically normal women. *Hum Rep* 1990; 5: 157-162.
 111. Filicori M, Flamigni C, Cognigni GE, Falbo A, Arnone R, Capelli M, Pavani A, Mandini M, Calderoni P, Brondelli L. Differential gonadotropin and leuporelin ovulation induction regimen markers affect follicular fluid hormone levels and folliculogenesis. *Fertil Steril* 1996; 65: 387-393
 112. Ho PC, Chan YF, So WK, Yeung WS, Chan ST. Luteinizing hormone (LH) surge in patients using buserelin spray during ovulation stimulation for assisted reproduction. *Asia Oceania J Obstet Gynaecol* 1993;19:159-163
 113. Fluker MR, Hooper WM, Yuzpe AA. Withholding gonadotropins ('coasting') to minimize the risk of ovarian hyper stimulation during superovulation and *in vitro* fertilization embryo transfer cycles. *Fertil Steril* 1999; 71: 294-301

114. Egbase PE, Sharhan MA, Grudzinskas JG. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. *Hum Reprod* 1999; 14 : 1421-1425
115. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman L, Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. *Hum. Reprod.* 2003;18:2698-2703.
116. Biljan MM, Mahutte NG, Dean N Hemmings R, Bissonnette F, Tan SL Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. *Fertil Steril* 1998; 70: 1063-1069
117. Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JA. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. *Cochrane Database Syst Rev* 2010; 20:CD006109
118. Kucuk T, Kozinoglu H, Kaba A. Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. *J Assist Reprod Genet* 2008;25:123-127
119. Empereire JC, Ruffie A. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. *Hum Reprod* 1991; 6: 506-510
120. Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, Caruso A, Mancuso S. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. *Fertil Steril* 1994; 62: 35-41
121. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin releasing hormone agonist to trigger follicular maturation for in vitro fertilization. *J Clin Endocrinol Metab* 1990; 71: 918-22
122. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. *Fertil Steril* 1991; 56: 213-220
123. Olivennes F, Fanchin R, Bouchard Ph, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) antagonist. *Fertil Steril* 1996; 66 :151-153
124. Itskovitz- Eldor J, Kol S, Mannaerts B. Use of single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. *Hum Reprod* 2000; 15: 1965-1968
125. Fauser BC, de Jong D, Olivennes F, Wramby H, Tay C, Itskovitz-Eldor J, van Hooren Hg. Endocrine profile after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. *J Clin Endocrinol Metab* 2002; 87: 709-715
126. Humaidan P, Bredkjaer H, Bungum L, Bungum M, Grondahl M, Westergaard L, Andersen C. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ ICSI cycles: a prospective randomized study. *Hum Reprod* 2005; 20: 1213-1220
127. Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRH α to trigger final oocyte maturation: a time to reconsider. *Hum REprod* 2009; 24: 2389-2394
128. Smitz J, Erard P, Camus M, Devroey P, Tounaye H, Wisanto A, Van Steirteghem AC: Pituitary gonadotropin secretory capacity during the luteal phase in superovulation using GnRH- agonists and HMG in a desensitization or flare-up protocol. *Hum Reprod* 1992; 7: 1225-1229
129. Qublan HS, Amarin Z, Tahat YA, Smadi AZ, Kilani M. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact. *Hum Reprod* 2006; 21: 640- 644
130. Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin- releasing hormone for in vitro fertilization: a Europe series and a proposal for prevention. *Fertil Steril* 1990; 53: 502-509
131. Lahat E, Raziell A, Friedler S, Schieber-Kazir M, Rom-El R. Long-term follow-up of children born after inadvertent administration of a gonadotropin- releasing hormone agonist in early pregnancy. *Hum Reprod* 1999;14: 2656-2660
132. Speroff L. Glass RH. Kase NG *Clinical Gynecologic Endocrinology and Infertility*. 6. Edition. p.152
133. Waibel- Treber S, Minne HW, Scharia SH, Bremen T, Ziegler R, Leyendecker G. Reversible bone loss in women treated with GnRH- agonists for endometriosis and uterine leiomyoma. *Hum Reprod* 1989; 4:384- 388